Table 1 Characteristics of included studies.

From: Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis

Study

ClinicalTrials.gov Identifier

Location

Blind

Phase

Follow up (years)

Mean age (years)

Male (%)

Total subject

Treatment

Control

AWARD-2 45

NCT01075282

Multicenter

Open label

phase III

1.5

56.66

51.3

807

Dulaglutide 0.75–1.5 mg QW for 78 weeks (n = 545)

Insulin SC once daily for 78 weeks; dose titration based on blood glucose measures (n = 262)

AWARD-4 46

NCT01191268

Multicenter

Open label

phase III

1

59.36

53.5

884

Dulaglutide 0.75–1.5 mg QW for 52 weeks (n = 588)

Insulin SC once daily for 52 weeks; dose titration based on blood glucose measures (n = 296)

LEAD-3 47

NCT00294723

Multicenter

Double blind

phase III

2

53

49.7

745

Liraglutide 1.8 mg QD for 104 weeks (n = 497)

Glimepiride 8 mg QD for 104 weeks (n = 248)

Nauck, 2007 48

NCT00082407

Multicenter

Open-label

phase III

1

58.7

48.7

501

Exenatide 5 mcg SQ BID for 4 weeks and followed by 10 mcg for 48 weeks (n = 253)

Insulin SC twice daily; titration to target blood glucose level (n = 248)

LEAD-2 49

NCT00318461

Multicenter

Double blind

phase III

2

56.7

58.2

1087

Liraglutide 0.6–1.8 mg/day for 104 weeks (n = 724)

Glimepiride 4 mg/day for 104 weeks (n = 242)/ Metformin 1.5–2.0 g/day for 140 weeks (n = 121)

HARMONY-1 50

NCT00849056

Multicenter

Double blind

phase III

1

55

59.8

301

Albiglutide 30 mg QW (n = 150)

Placebo (n = 151)

Seino, 2010 51

NCT00393718

Japan

Double blind

phase III

1

58.3

67.3

400

Liraglutide 0.9 mg/day for 52 weeks (n = 268)

Glibenclamide 2.5 mg/day for 52 weeks (n = 132)

AWARD-1 2014 52

NCT01064687

Multicenter

Double blind

phase III

1

56.5

58.4

979

Dulaglutide 0.75–1.5 mg QW or Exenatide 5 mcg BID for 4 weeks, followed by 10 mcg BID for 48 weeks (n = 837)

Placebo (n = 142)

HARMONY-4 2014 53

NCT00838916

Multicenter

Open-label

phase III

1

55.5

56.1

745

Albiglutide 30 mg QW, n = 504

Insulin, n = 241

Seck 2010 54

NCT00094770

NR

Double blind

phase III

2

57.3

60.1

1172

Sitagliptin 100 mg QD (n = 588)

Glipizide 5 mg QD (n = 584)

Rosenstock 2013 55

NCT00121641

Multicenter

Double blind

phase III

2

53.5

50.1

401

Saxagliptin 2.5–10 mg QD (n = 301)

Placebo (n = 95)

DeFronzo 2009 56

NCT00121667

Multicenter

Double blind

phase III

4

54.6

50.7

743

Saxagliptin 2.5–10 mg QD (n = 564)

Placebo (n = 179)

Dobs 2013 57

NCT00350779

Multicenter

Double blind

phase III

1

54.6

58

262

Sitagliptin 100 mg QD (n = 170)

Placebo (n = 92)

EUREXA 2012 58

NCT00359762

Multicenter

Open-label

phase III

1

56.4

53.6

1019

Exenatide 10 mcg BID, n = 511

Glimepiride 1 mg QD, n = 508

Bosi 2011 59

NCT00432276

Multicenter

Double blind

phase III

1

55.1

51.5

803

Alogliptin 25 mg QD (n = 404)

Placebo (n = 399)

Corry 2013 60

NCT00509236

Multicenter

Double blind

phase III

1

59.5

59.7

129

Sitagliptin 25 mg QD (n = 64)

Glipizide 2.5–20 mg QD (n = 65)

Arjona 2013 61

NCT00509262

Multicenter

Double blind

phase III

1

64.6

57.1

422

Sitagliptin 25–50 mg QD (n = 210)

Glipizide 2.5–20 mg QD (n = 212)

Gallwitz 2012 62

NCT00622284

Multicenter

Double blind

phase III

2

59.8

61

1551

Linagliptin 5 mg QD (n = 776)

Glimepiride 1 mg QD (n = 775)

Göke 2013 63

NCT00575588

Multicenter

Double blind

phase III

2

57.6

51.7

858

Saxagliptin 5 mg QD (n = 428)

Glipizide 5–20 mg QD (n = 430)

Wilson 2013 64

NCT00707993

Multicenter

Double blind

phase III

1

69.9

44.9

441

Alogliptin 25 mg QD (n = 222)

Glipizide 5–10 mg QD (n = 219)

AWARD-5 2015 65

NCT00734474

Multicenter

Double blind

phase III

2

54

46.7

921

Sitagliptin 100 mg QD (n = 315)

Dulaglutide 0.75–1.5 mg QW (n = 606)

Barnett 2012 66

NCT00740051

Multicenter

Double blind

phase III

1

56.6

39.9

227

Linagliptin 5 mg QD (n = 151)

Placebo (n = 76)

Barnett 2013 67

NCT00757588

Multicenter

Double blind

phase IIIb

1

57.3

57.8

455

Saxagliptin 5 mg QD (n = 304)

Placebo (n = 151)

TECOS 2015 68

NCT00790205

Multicenter

Double blind

phase III

3

65.5

70.3

14523

Sitagliptin 100 mg QD (n = 7332)

Placebo (n = 7339)

HARMONY-3 2014 69

NCT00838903

Multicenter

Double blind

phase III

2

54.5

47.6

1012

Sitagliptin 100 mg QD (n = 302)

Glimepiride 2 mg QD (n = 307) /Albiglutide 30 mg QW (n = 302) /Placebo (n = 101)

Del 2014 70

NCT00856284

Multicenter

Double blind

phase III

2

55.4

49.7

2639

Alogliptin 12.5 mg QD (n = 1765)

Glipizide 5–20 mg QD (n = 874)

Ferrannini 2013 71

NCT00881530

Multicenter

Open- Label

phase II

1.5

58.9

44.3

388

Sitagliptin 100 mg QD (n = 56)

Empagliflozin 10–25 mg QD (n = 332)

Yki-Järvinen 2013 72

NCT00954447

Multicenter

Double blind

phase III

1

60

52.2

1261

Linagliptin 5 mg (n = 631)

Placebo (n = 630)

EXAMINE 2013 73

NCT00968708

Multicenter

Double blind

phase III

1.5

61

67.9

5380

Alogliptin 25 mg QD (n = 2701)

Placebo (n = 2679)

GENERATION 2015 74

NCT01006603

Europe,Mexico

Double blind

phase IIIb/IV

1

72.6

61.8

720

Saxagliptin 5 mg QD (n = 360)

Glimepiride 1 mg QD (n = 360)

Lavalle-González 2013 75

NCT01106677

Multicenter

Double blind

phase III

1

55.4

46.4

1101

Sitagliptin 100 mg QD (n = 366)

Canagliflozin 100–300 mg QD (n = 735)

SAVOR-TIMI 53 2013 76

NCT01107886

Multicenter

Double blind

phase IV

2.1

65

67

16492

Saxagliptin 5 mg QD (n = 8280)

Placebo (n = 8212)

CANTATA-D2 2013 72

NCT01137812

Multicenter

Double blind

phase III

1

56.5

55.9

755

Sitagliptin 100 mg QD (n = 378)

Canagliflozin 300 mg QD (n = 378)

ELIXA 2016 77

NCT01147250

Multicenter

Open-label

phase III

2.1

60.3

69.4

6068

Lixisenatide 10–20 μg QD, n = 3034

Non-medication, n = 3034

Roden 2015 45

NCT01289990

Multicenter

Open-Label

phase III

1.5

55

61.3

899

Sitagliptin 100 mg QD (n = 223)

Empagliflozin 10 mg/25 mg QD (n = 448)

 

NCT01098539 (139)

Multicenter

Double blind

phase III

1

63.3

53.7

495

Albiglutide 30 mg QW (n = 249)

Sitagliptin 100 mg QD (n = 246)

 

NCT01075282(75)

Multicenter

Open-label

phase III

1.5

56.7

51.3

807

Dulaglutide 1.5 mg SC QW for 78 weeks, n = 545

Insulin, n = 262

 

NCT01648582(49)

Multicenter

Open-label

phase III

1

54.5

54.5

783

Dulaglutide 0.75–1.5 mg QW for 52 weeks, n = 526

Insulin, n = 257

 

NCT01087502(36)

Multicenter

Double blind

phase III

1

66.6

63.4

235

Linagliptin 5 mg (n = 118)

Placebo for 12 weeks and then switch to Glimepiride for further 40 weeks (n = 123)

 

NCT01682759 (108)

Multicenter

Double blind

phase III

1

57.7

55.1

751

Omarigliptin 25 mg QW (n = 375)

Glimepiride 1–6 mg QD (n = 376)

  1. QD = once daily. BID = twice daily. QW = once per week. SC = subcutaneous. n = nu mber of participants. Registration number were identify in ClinicalTrials.gov.
Back to article page